Langhorne, PA-based Alliqua Biomedical in July reported that its exclusive licensing agreement with Summit, NJ-based Celgene Cellular Therapeutics now includes the right to market an advanced wound care product for podiatric and orthopedic applications.
Biovance is a decellularized, dehydrated, human amniotic membrane allograft indicated for management of uninfected partial- and full-thickness wounds, and now, for repair of tendon, nerve, and bone in the foot and ankle.
Lower Extremity Review or LER Magazine fills the lower extremity injury information gap for lower extremity practitioners in the fields of lower limb orthotics, lower limb prosthetics, lower limb O&P, podiatry, pedorthic, lower extremity physical therapy, foot and ankle, pediatric, sports medicine, orthopedic and athletic trainer markets interested in prefabricated and custom ankle and knee bracing, ACL, off-the-shelf and custom ligament knee bracing, osteoarthritis knee bracing, insoles, full contact diabetic foot inserts, orthotic materials, multi-density inserts, dual density insoles, custom foot orthotics, night splints, standard and hinged AFOs, diabetic footwear, diabetic socks, pressure measurement, sports medicine, neuromuscular disorders, stroke, drop foot, PTTD, flat foot, rehabilitation and biomechanics. LER Magazine bridges the gap between lower extremity foot orthotics, custom and prefabricated ankle and knee bracing, diabetic custom foot orthotics and diabetic foot wear, shoe manufacturers and lower extremity central fabricators with lower extremity practitioners by providing:
© 2009-2022 Copyright Lower Extremity Review Magazine. All rights reserved.
